L. A. VanBlargan

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.